SCHEMBL25513877

SCHEMBL25513877

COC(=O)C(O)(CCC(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.39
NAALAD2 Q9Y3Q0 1/20 0.39
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 1/20 0.34
CA12 O43570 3/20 0.33
CA14 Q9ULX7 3/20 0.33
CA2 P00918 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTPRB P23467 1/20 0.32
CTSK P43235 4/20 0.32
CA1 P00915 3/20 0.32
CA7 P43166 3/20 0.32
TSHR P16473 1/20 0.32
MAPT P10636 1/20 0.32
CTSS P25774 2/20 0.31
APLNR P35414 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25515595 1.00 DGAT1 (0.39) DGAT1NAALAD2MEN1KMT2AGAA
SCHEMBL4792294 0.81 DGAT1 (0.45) DGAT1MEN1KMT2AGAACA12
SCHEMBL29383045 0.81 DGAT1 (0.45) DGAT1MEN1KMT2AGAACA12
SCHEMBL23849146 0.79 DGAT1 (0.38) DGAT1NAALAD2MEN1KMT2AGAA
SCHEMBL31239045 0.79 DGAT1 (0.42) DGAT1NAALAD2MEN1KMT2AGAA
SCHEMBL25514934 0.79 DGAT1 (0.38) DGAT1NAALAD2MEN1KMT2AGAA
SCHEMBL18923231 0.78 DGAT1 (0.42) DGAT1MEN1KMT2AGAACA12
SCHEMBL3031112 0.75 NAALAD2 (0.65) NAALAD2MEN1KMT2AGAACA12
SCHEMBL8971824 0.75 NAALAD2 (0.65) NAALAD2MEN1KMT2AGAACA12
SCHEMBL25515213 0.74 CAPN1 (0.33) PTPRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION ASNS, GLUL, GNMT DGAT1 1691/4885NAALAD2 33/4885MEN1 3555/4885
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 DGAT1 4025/4885NAALAD2 1153/4885MEN1 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.